All In Biotech

Drug Trial Radar · NCT05650632

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of Etentamig (ABBV-383) in Subjects With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Mar 21, 2023

Primary completion

Aug 2029

Study completion Aug 2029

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of etentamig (ABBV-383) in adult participants with relapsed/refractory (R/R) MM. Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study is broken into 4 Arms; Arm A (Parts 1 and 2), Arm B and Arms C \& D. Arm A includes 2 parts: step-up dose optimization (Part 1) and dose expansion (Part 2). In Part 1, different level of step-up doses are tested followed by the target dose of etentamig (ABBV-383). In Part 2, the step-up dose identified in Part 1 (Dose A) will be used followed by the target dose A of etentamig (ABBV-383). In Arm B a flat dose of etentamig (ABBV-383) will be tested. In Arms C \& D, the step-up dose identified in Arm A will be used followed by the target dose of etentamig (ABBV-383) to investigate outpatient administration of etentamig (ABBV-383). In Arm E, etentamig (ABBV-383) will be investigated for outpatient administration. Around 250 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 50 sites across the world. Participants will receive etentamig (ABBV-383) as an infusion into the vein in 28 day cycles for approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Conditions

  • Multiple Myeloma

Interventions

  • Etentamig (ABBV-383)Drug

    Intravenous Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arm A (Part 1 and Part 2) Arm C, Arm D, and Arm E: Number of Grade >= 2 Cytokine Release Syndrome (CRS) EventsTime frame: Up to Day 28
  2. Arm B: Number of Adverse Events (AEs) of Special Interest (CRS and Immune Effector Cell-associated Neurotoxicity Syndrome [ICANS])Time frame: Up to Day 28

Locations

44 sites in 7 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona /ID# 251405

    Phoenix, Arizona · Recruiting

  • Highlands Oncology Group - Springdale /ID# 267742

    Springdale, Arkansas · Recruiting

  • Rocky Mountain Cancer Centers - Aurora /ID# 268574

    Aurora, Colorado · Recruiting

  • Medical Oncology Hematology Consultants /ID# 268560

    Newark, Delaware · Recruiting

  • Hope And Healing Cancer Services /ID# 268536

    Hinsdale, Illinois · Recruiting

  • Fort Wayne Medical Oncology And Hematology /ID# 268179

    Fort Wayne, Indiana · Recruiting

  • Franciscan St. Francis Health /ID# 280928

    Indianapolis, Indiana · Recruiting

  • East Jefferson General Hospital /ID# 251204

    Metairie, Louisiana · Recruiting

  • Mayo Clinic - Rochester /ID# 251164

    Rochester, Minnesota · Recruiting

  • NHO Revive Research Institute, LLC /ID# 267869

    Lincoln, Nebraska · Recruiting

  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497

    Omaha, Nebraska · Recruiting

  • Icahn School of Medicine at Mount Sinai /ID# 251166

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center-Koch Center /ID# 251167

    New York, New York · Recruiting

  • University of North Carolina /ID# 251203

    Chapel Hill, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist Medical Center /ID# 251165

    Winston-Salem, North Carolina · Recruiting

  • University Of Cincinnati Medical Center /ID# 251746

    Cincinnati, Ohio · Recruiting

  • Willamette Valley Cancer Institute and Research Center /ID# 267088

    Eugene, Oregon · Recruiting

  • Vanderbilt Ingram Cancer Center /ID# 252470

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Central/South Texas /ID# 268563

    Austin, Texas · Recruiting

  • Texas Oncology - Dallas - Worth Street /ID# 280064

    Dallas, Texas · Recruiting

  • Oncology Consultants /ID# 268323

    Houston, Texas · Recruiting

  • Texas Oncology - Northeast Texas /ID# 268877

    Tyler, Texas · Recruiting

  • Virginia Cancer Specialists - Fairfax /ID# 268559

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Center - Seattle - Eastlake Avenue East /ID# 267940

    Seattle, Washington · Recruiting

  • Northwest Medical Specialties Tacoma /ID# 267117

    Tacoma, Washington · Recruiting

  • Juravinski Cancer Centre /ID# 252053

    Hamilton, Ontario, Canada · Recruiting

  • Ottawa Hospital Research Institute /ID# 252151

    Ottawa, Ontario, Canada · Completed

  • Odense University Hospital /ID# 251261

    Odense, Region Syddanmark, Denmark · Recruiting

  • Vejle Sygehus /ID# 251260

    Vejle, Region Syddanmark, Denmark · Recruiting

  • AP-HP - Hopital Saint-Antoine /ID# 252326

    Paris, France · Completed

  • Institut Paoli-Calmettes /ID# 252100

    Marseille, Bouches-du-Rhone, France · Completed

  • Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 252101

    Créteil, Paris, France · Completed

  • Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 251196

    Nantes, Pays de la Loire Region, France · Recruiting

  • HCL - Hopital Lyon Sud /ID# 251223

    Pierre-Bénite, Rhone, France · Recruiting

  • CHU Poitiers - La miletrie /ID# 251219

    Poitiers, Vienne, France · Recruiting

  • Rabin Medical Center. /ID# 251330

    Petah Tikva, Central District, Israel · Recruiting

  • Hadassah Medical Center-Hebrew University /ID# 252079

    Jerusalem, Jerusalem, Israel · Recruiting

  • The Chaim Sheba Medical Center /ID# 251329

    Ramat Gan, Tel Aviv, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center /ID# 251573

    Tel Aviv, Tel Aviv, Israel · Recruiting

  • Hospital Universitario de Salamanca /ID# 251529

    Salamanca, Spain · Recruiting

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.